Erratum to Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan[Cancer Microenvironment, DOI 10.1007/s12307-014-0161-7];Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan

Cancer Microenvironment

Volumn 8, Issue 1, 2015, Pages 33-41

  Vogelhuber, M ^a   Feyerabend, S ^b   Stenzl, A ^b   Suedhoff, T ^c   Schulze, M ^d   Huebner, J ^e   Oberneder, R ^f   Wieland, W ^g   Mueller, S ^h   Eichhorn, F ⁱ   Heinzer, H ^j   Schmidt, K ^k   Baier, M ^k   Ruebel, A ^k   Birkholz, K ^k   Bakhshandeh Bath, A ^l   Andreesen, R ^a   Herr, W ^a   Reichle, A ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Department of Internal Medicine   (Germany)

^d Outpatient Center for Urology and Oncology   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f Urologic Hospital München Planegg   (Germany)

^g UNIVERSITY OF REGENSBURG   (Germany)

^h UNIVERSITY HOSPITAL BONN   (Germany)

ⁱ Outpatient Center   (Germany)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k Novartis Pharma GmbH   (Germany)

^l Outpatient Center for Medical Oncology   (Germany)

more..

Author keywords

Castration resistant prostate cancer; Multi targeted, biomodulatory therapy; PSA response; Quality of life

Indexed keywords

DEXAMETHASONE; ETORICOXIB; GLUCOCORTICOID; IMATINIB; LACTATE DEHYDROGENASE; PIOGLITAZONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TREOSULFAN;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; BODY WEIGHT; BONE METASTASIS; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FACE EDEMA; FATIGUE; GASTROINTESTINAL DISEASE; HEART ARREST; HEMATOLOGIC DISEASE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INFECTION; INFESTATION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATECTOMY; QUALITY OF LIFE; RESPIRATORY ARREST; RESPIRATORY DISTRESS SYNDROME; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; VERY ELDERLY; VOMITING;

EID: 84930081585     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-015-0165-y     Document Type: Erratum

References (39)

1. Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138–148
2. Osanto S, Van Poppel H (2012) Emerging novel therapies for advanced prostate cancer. Ther Adv Urol 4:3–12
3. Hurwitz M, Petrylak DP (2013) Sequencing of agents for castration-resistant prostate cancer. Oncology (Williston Park) 27(11):1144–1149, 1154–8
4. Reichle A, Vogt T (2008) Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron 1:159–170
5. Jain G, Cronauer MV, Schrader M et al (2012) NF-κB signaling in prostate cancer: a promising therapeutic target? World J Urol 30:303–310
6. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
7. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26:1148–1159
8. Walter B, Rogenhofer S, Vogelhuber M (2010) Modular therapy approach in metastatic castration-refractory prostate cancer. World J Urol 28:745–750
9. Ustach CV, Huang W, Conley-LaComb MK et al (2010) A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer. Cancer Res 70:9631–9640
10. Mathew P, Thall PF, Jones D et al (2004) Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 22:3323–3329
11. Kim SJ, Uehara H, Yazici S et al (2006) Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98:783–793
12. Nakamura Y, Suzuki T, Sugawara A et al (2009) Peroxisome proliferator-activated receptor gamma in human prostate carcinoma. Pathol Int 59:288–293
13. Matsuyama M, Yoshimura R (2008) Peroxisome proliferator-activated receptor-gamma is a potent target for prevention and treatment in human prostate and testicular cancer. PPAR Res:249849
14. Smith MR, Manola J, Kaufman DS et al (2004) Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 101:1569–1574
15. Shockley KR, Lazarenko OP, Czernik PJ et al (2009) PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 106:232–246
16. Storlie JA, Buckner JC, Wiseman GA et al (1995) Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76:96–100
17. Nishimura K, Nonomura N, Yasunaga Y et al (2000) Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89:2570–2576
18. Keith BD (2008) Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. BMC Cancer. doi:10.1186/1471-2407-8-84
19. Komiya A, Shimbo M, Suzuki H, Imamoto T, Kato T, Fukasawa S, Kamiya N, Naya Y, Mori I, Ichikawa T (2010) Oral low-dose dexamethasone for androgen-independent prostate cancer patients. Oncol Lett 1(1):73–79
20. Khor LY, Bae K, Pollack A et al (2007) COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92–02 trial. Lancet Oncol 8:912–920
21. Emmenegger U, Chow A, Bocci G (2010) The biomodulatory capacities of low-dose metronomic chemotherapy: complex modulation of the tumor microenvironment. In: Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, pp 243–262
22. Feyerabend S, Feil G, Krug J et al (2007) Cytotoxic effects of treosulfan on prostate cancer cell lines. Anticancer Res 27(4B):2403–2408
23. Nelius T, Rinard K, Filleur S (2011) Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature. Cancer Treat Rev 37:444–455
24. Glode LM, Barqawi A, Crighton F et al (2003) Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98:1643–1648
25. Heidenreich A, Aus G, Bolla M et al (2008) EAU guidelines on prostate cancer. Eur Urol 53:68–80
26. European Organisation for Research and Treatment of Cancer (EORTC) http://www.eortc.be/home/qol/files/SCManualQLQ-C30.pdf Accessed 4 September 2012
27. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11(4):607–615
28. Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245
29. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F et al (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481–1488
30. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC et al (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489–1495
31. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, Ouyang P, Kelly WK, Scher HI (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17(3):948–957
32. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520
33. Morant R, Bernhard J, Dietrich D et al (2004) Capecitabine in hormone-resistant metastatic prostatic carcinoma—a phase II trial. Br J Cancer 90:1312–1317
34. Pitteri SJ, Kelly-Spratt KS, Gurley KE et al (2011) Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 71:5090–5100
35. Oprea TI, Bauman JE, Bologa CG et al (2011) Drug repurposing from an academic perspective. Drug Discov Today Ther Strat 8(3–4):61–69
36. Berry DA (2011) Adaptive clinical trials in oncology. Nat Rev Clin Oncol 9:199–207
37. Squire JA, Park PC, Yoshimoto M et al (2011) Prostate cancer as a model system for genetic diversity in tumors. Adv Cancer Res 112:183–216
38. Bellmunt J (2008) Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol 55:1310–1312
39. Koroukian SM, Murray P, Madigan E (2006) Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. J Clin Oncol 24:2304–2310